$TEVA · TEVA PHARMACEUTICAL INDUSTRIES LTD
Teva filed its Q3 2026 10-Q, reporting net revenue of $4.395B (-1.9% YoY), GAAP EPS of $0.20 (down from $0.38), and net income attributable to Teva of $233M (down from $433M). Gross margin improved to 55.5% from 51.4% YoY, but operating income fell to $714M from $882M as financial expenses nearly doubled to $414M and restructuring/legal charges weighed on results.
- Q3 revenue of $4.395B fell 1.9% YoY from $4.480B, with U.S. generics revenue collapsing 39% to $718M from $1.175B.
- GAAP EPS dropped to $0.20 from $0.38 YoY; nine-month GAAP EPS cratered to $0.02 from $0.81.
- Financial expenses surged to $414M in Q3 from $237M YoY, a 75% increase that crushed pre-tax income.
- R&D expenses jumped 16% YoY to $297M in Q3; nine-month R&D nearly doubled to $1.489B from $746M.
- AUSTEDO remained the bright spot: Q3 revenue of $727M (+21% YoY) and nine-month revenue of $1.963B (+32% YoY).
Extended-hours trading shows TEVA at $41.90, essentially flat (-0.02%) vs the regular-session close of $41.91. The market appears to have largely priced in the revenue decline and earnings compression given the modest after-hours move.
Teva's Pivot to Growth strategy is showing a stark divergence: AUSTEDO is booming (+32% nine-month) while U.S. generics are in freefall (-39% Q3), and surging financial expenses are consuming the margin gains.
Teva's U.S. generics segment is under severe pressure — a 39% YoY revenue drop mirrors broader generic pricing deflation but is amplified by the Anda segment reclassification. The pivot toward branded innovative medicines (AUSTEDO, AJOVY, UZEDY) is showing traction but not yet offsetting the legacy portfolio erosion.
The filing flags the October 2026 agreement with the U.S. Administration following executive orders targeting prescription drug pricing, including most-favored-nation pricing. The OBBBA legislation is expected to reduce insured populations in Medicaid and Health Insurance Exchange markets, potentially shifting payer leverage. The planned API business divestiture also introduces execution risk.